Mitoxantrone-DHAP with GM-CSF: An Active but Myelosuppressive Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

References

• Fisher R. I., Gaynor E. R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. The New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Velasquez W. S., Cabanillas F., Salvador P. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Nichols C. R., P. J. L., Greist A., et al. Salvage chemotherapy for lymphoma with VP-16, ifosfamide, and cisplatin. Medical and Pediatric Oncology 1988; 16: 12–16
   PubMedGoogle Scholar
• Dana B., Dahlberg S., Schnitzer B., et al. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A. Southwest Oncology Group Phase II trial. Investigational New Drugs 1989; 7: 247–250
   PubMed Web of Science ®Google Scholar
• Cornelia P., Abate G., Di Finizio G., et al. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, and bleomycin. Cancer Chemotherapy and Pharmacology 1990; 26: 306–309
   PubMed Web of Science ®Google Scholar
• Goss P. E., Sheperd F. A., Scott J. G., et al. Dexamethasone, ifosfamide, cisplatin, etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: Preliminary report of a phase II study. Annuls of Oncology 1991; 2: 43–46
   PubMed Web of Science ®Google Scholar
• Paciucci P. A., Crown J. C., Holland J. F. Mitoxantrone, Vincristine, and Dexamethasone in patients with refractory lymphoma. American Journal of Clinical Oncology 1989; 12: 327–331
   PubMed Web of Science ®Google Scholar
• Silver R. T., Case D. C., Jr., Wheeler R. H., et al. Multicenter clinical trial of mitoxantrone in non-Hodkin's lymphoma and Hodkin's Disease. Journal of Clinical Oncology 1991; 9: 754–761
   PubMed Web of Science ®Google Scholar
• Dupriez B., Morel P., Fenaux P., et al. VIM3-ARA C: An effective salvage regimen in refractory or recurrent aggressive non-Hodgkin's lymphoma. A report on 18 cases. Haematological Oncology 1991; 9: 259–266
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., McLaughlin P., et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. Journal of Clinical Oncology 1987; 5: 407–412
   PubMed Web of Science ®Google Scholar
• Cabanillas F., Hagemeister F. B., Bodey G. P., et al. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697
   PubMed Web of Science ®Google Scholar
• Hayat M., Ostronoff M., Gilles E., et al. Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma. Cancer Investigation 1990; 8: 1–5
   PubMed Web of Science ®Google Scholar
• Stewart A. K., J. M. B., Sutcliffe S. B. I. Mini-Beam as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leukemia and Lymphoma 1991; 5: 111–115
   PubMed Web of Science ®Google Scholar
• Philip T., Armitage J. O., Spitzer G., et al. High dose therapy and ABMT after failure of conventional chemotherapy in adults with intermediate grade or high grade NHL. The New England Journal of Medicine 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Sullivan K. M., Buckner C. D. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. Journal of Clinical Oncology 1987; 5: 1340–1347
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Fay J. W., Herzig R. H. The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990; 75: 831–838
   PubMed Web of Science ®Google Scholar
• Peterson F. B., Appelbaum F. R., Hill R. Autologous marrow transplantation for malignant lymphomas. A report of 101 cases from Seattle. Journal of Clinical Oncology 1990; 8: 638–647
   PubMed Web of Science ®Google Scholar
• Takvorian T., Canellos G. P., Ritz J. Prolonged disease-free survival after ABMT in patients with NHL with poor prognosis. The New England Journal of Medicine 1987; 316: 1499–1505
   PubMed Web of Science ®Google Scholar
• Freedman A. S., Takvorian T., Anderson K. C. Autologous bone marrow transplantation in B-cell NHL: Very low treatment related mortality in 100 patients with sensitive relapse. Journal of Clinical Oncology 1990; 8: 784–791
   PubMed Web of Science ®Google Scholar
• Canellos G. P., Nadler L., Tak T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. Seminars in Hematology 1988; 25: 58–65
   PubMed Web of Science ®Google Scholar
• Bosly A., Coiffier B., Gisselbrecht C. Intensive chemotherapy plus hematopoietic stem cells transplantation for relapsing non-Hodgkin's lymphoma: the GELA experience. Nouvelle Revue Française d'Hématologie 1993; 35: 21–23
   PubMedGoogle Scholar
• Cortelazzo S., Viero P., Bellavita P. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. Journal of Clinical Oncology 1995; 13: 935–94
   PubMed Web of Science ®Google Scholar
• Klumpp T. R., Mangan K. F., Goldberg S. L., et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. Journal of Clinical Oncology 1995; 13: 1323–1327
   PubMed Web of Science ®Google Scholar
• Philip T., Hartmann O., Biron P. High dose therapy and autologous bone marrow transplantation in partial response after first line induction therapy for diffuse NHL. Journal of Clinical Oncology 1988; 6: 1118–1124
   PubMed Web of Science ®Google Scholar
• Philip T., Chauvin F., Armitage J., et al. Parma International Protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991; 77: 1587–1592
   PubMed Web of Science ®Google Scholar
• Philip T., Gugliemi C., Chauvin F. Autologous Bone Marrow transplantation (ABMT) versus (vs) conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma (NHL); final analysis of the PARMA randomized study (216 patients), (Abstr). Proceedings of the American Society of Clinical Oncology. 1995; 14
   Google Scholar
• Neidhart J. A., Kubica R., Stidley C. Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Investigation 1994; 12: 1–11
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Hryniuk W. M., Goodyear M. D. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology 1991; 9: 339–347
   PubMed Web of Science ®Google Scholar
• Skipper H. E., Schabel F. M., Jr., Wilcox W. S. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemotherapy Reports 1964; 35: 1
   PubMedGoogle Scholar
• Frei E., III, Teicher B. A., Holden S. A. Preclinical studies and clinical correlation of the effect of Alkylator dose. Cancer Research 1988; 48: 6417
   PubMed Web of Science ®Google Scholar
• Press O. W., Livingston R., Mortimer J., et al. Treatment of relapsed non-Hodgkin's lymphomas with DHAP before bone marrow transplantation. Journal of Clinical Oncology 1991; 9: 423–431
   PubMed Web of Science ®Google Scholar
• Montillo M., Tedeschi A., Capelli D., et al. Efficacy of DHAP regimen in relapsed and refractory lymphomas with or without major ablative therapy (Abstr). Proceedings of the American Society of Clinical Oncology 1995; 14: 400
   Google Scholar
• Neidhart J. A. Pixy 321 support of chemotherapy with carboplatin and dose intensive Cytoxan, Vp-16 and cisplatin (DICEP). Biotechnology and Therapies 1993
   PubMedGoogle Scholar
• Velasquez W., Hagemeister F., McLaughlin P., et al. E-SHAP: An effective treatment for refractory and relapsing lymphoma. A long follow-up (Abstr). E-SHAP: An effective treatment for refractory and relapsing lymphoma. A long follow-up (Abstr). 1992; 11: 326
   Google Scholar
• Johnson P. W. M., Sweetenham J. W., McCallum P., et al. E-SHAP: Inadequate treatment for poor-prognosis recurrent lymphoma. Annals of Oncology 1993; 4: 63–67
   PubMed Web of Science ®Google Scholar
• Aparicio U. J., Gomez C. J., Molins P. C. Quimioterapia de rescate en la enfermedad de Hodgkin y los linfomas no hodgkinianos con etoposido, metilprednisolona, altas dosis de ara-C y cisplatino (E-SHAP). Neoplasia 1993; 10: 48–53
   Google Scholar
• Ezzat A. A., Khalifa F., Berry J., et al. E-SHAP: An effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Proceedings of the American Society of Clinical Oncology 1994; 13: 383
   Google Scholar